| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR3DL2 |
| Uniprot No | P43630 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-340aa |
| 氨基酸序列 | ADPLMGGQDKPFLSARPSTVVPRGGHVALQCHYRRGFNNFMLYKEDRSHV PIFHGRIFQESFIMGPVTPAHAGTYRCRGSRPHSLTGWSAPSNPLVIMVT GNHRKPSLLAHPGPLLKSGETVILQCWSDVMFEHFFLHREGISEDPSRLV GQIHDGVSKANFSIGPLMPVLAGTYRCYGSVPHSPYQLSAPSDPLDIVIT GLYEKPSLSAQPGPTVQAGENVTLSCSSWSSYDIYHLSREGEAHERRLRA VPKVNRTFQADFPLGPATHGGTYRCFGSFRALPCVWSNSSDPLLVSVTGN PSSSWPSPTEPSSKSGICRHLHVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGKHHHHHH |
| 预测分子量 | 62 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR3DL2重组蛋白的3篇参考文献示例(基于真实研究方向的模拟摘要，具体文献详情建议通过学术数据库核实)：
---
1. **文献名称**: "Molecular Cloning and Functional Characterization of KIR3DL2"
**作者**: Pessino, A., et al.
**摘要**: 该研究首次克隆了KIR3DL2的cDNA，并通过重组蛋白技术在哺乳动物细胞中表达。研究揭示了KIR3DL2在自然杀伤(NK)细胞和T细胞亚群中的表达模式，并证实其与HLA-A3/A11等位基因的特异性结合能力。
---
2. **文献名称**: "KIR3DL2 Interaction with HLA-A3/A11 in Cutaneous T-cell Lymphoma"
**作者**: Bagot, M., et al.
**摘要**: 本文探讨了KIR3DL2在皮肤T细胞淋巴瘤(CTCL)中的异常表达，利用重组KIR3DL2蛋白进行体外结合实验，证明其与肿瘤细胞表面的HLA-A3/A11配体结合可能促进疾病进展，为靶向治疗提供了依据。
---
3. **文献名称**: "Structural Insights into KIR3DL2-HLA Complexes via Recombinant Protein Crystallography"
**作者**: Blokhuis, J.H., et al.
**摘要**: 通过重组表达KIR3DL2蛋白及其HLA配体，本研究解析了KIR3DL2与HLA-A3的复合物晶体结构，揭示了受体-配体结合的关键界面，为免疫调节药物的设计提供了结构基础。
---
**备注**：以上文献信息为模拟示例，实际引用时请通过PubMed、Google Scholar等平台核对作者、标题及摘要准确性。如需具体文献指导，可提供更详细的研究方向或关键词进一步筛选。
**Background of KIR3DL2 Recombinant Protein**
KIR3DL2 (killer cell immunoglobulin-like receptor 3DL2) is a member of the KIR family, which regulates natural killer (NK) cell and T-cell activity by interacting with human leukocyte antigen (HLA) class I molecules. Structurally, KIR3DL2 is a transmembrane glycoprotein containing three extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based inhibitory motifs (ITIMs). As an inhibitory receptor, KIR3DL2 transmits suppressive signals upon binding to specific HLA ligands (e.g., HLA-A3/A11), dampening immune cell activation to prevent autoimmunity. However, its role may vary depending on cellular context and ligand engagement.
Recombinant KIR3DL2 protein is engineered in vitro using expression systems (e.g., mammalian or insect cells) to retain functional domains for research and therapeutic applications. It serves as a critical tool to study receptor-ligand interactions, signaling mechanisms, and its dual roles in immune regulation and disease. For instance, KIR3DL2 is implicated in pathologies like cutaneous T-cell lymphoma (CTCL), where malignant T-cells overexpress the receptor, making it a biomarker and therapeutic target. Recombinant KIR3DL2 aids in developing blocking antibodies (e.g., lacutamab) or fusion proteins to disrupt pro-survival signaling in cancer cells.
Additionally, recombinant KIR3DL2 is used in structural studies to map binding interfaces with HLA or pathogens (e.g., *Staphylococcus* superantigens), informing vaccine or drug design. Its role in viral infections, autoimmune disorders, and transplantation tolerance further underscores its biomedical relevance. By enabling precise biochemical and functional analyses, recombinant KIR3DL2 accelerates the translation of basic research into clinical interventions targeting immune dysregulation.
×
